FLU-PHARM

New drugs targeting influenza virus polymerase

 Coordinatore EUROPEAN MOLECULAR BIOLOGY LABORATORY 

 Organization address address: Meyerhofstrasse 1
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Mrs.
Nome: Sonja
Cognome: Noss
Email: send email
Telefono: 4962210000000
Fax: 4962210000000

 Nazionalità Coordinatore Germany [DE]
 Totale costo 8˙318˙210 €
 EC contributo 5˙998˙757 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-INFLUENZA-2010
 Funding Scheme CP-FP
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-11-01   -   2015-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    EUROPEAN MOLECULAR BIOLOGY LABORATORY

 Organization address address: Meyerhofstrasse 1
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Mrs.
Nome: Sonja
Cognome: Noss
Email: send email
Telefono: 4962210000000
Fax: 4962210000000

DE (HEIDELBERG) coordinator 991˙222.00
2    SAVIRA PHARMACEUTICALS GMBH

 Organization address address: VETERINARPLATZ 1
city: WIEN
postcode: 1210

contact info
Titolo: Dr.
Nome: Dirk
Cognome: Classen-Houben
Email: send email
Telefono: +43 1 250 77 59 04
Fax: +43 1 250 77 59 99

AT (WIEN) participant 1˙790˙507.00
3    ADVANCED TECHNOLOGY CORPORATION SA

 Organization address address: Inst. Pathology B23 CHU Sart Tilman
city: LIEGE
postcode: 4000

contact info
Titolo: Dr.
Nome: Patrice
Cognome: Chiap
Email: send email
Telefono: +32 4 3664350
Fax: +32 4 3662481

BE (LIEGE) participant 715˙075.00
4    "PRESTWICK CHEMICAL, INC."

 Organization address address: "K STREET, NW, SUITE 520 1825"
city: WASHINGTON
postcode: 20006

contact info
Titolo: Prof.
Nome: Thierry
Cognome: Langer
Email: send email
Telefono: +33 369 20 16 00
Fax: +33 369 20 16 17

US (WASHINGTON) participant 653˙190.00
5    AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

 Organization address address: CALLE SERRANO 117
city: MADRID
postcode: 28006

contact info
Titolo: Mr.
Nome: Carlos Manuel
Cognome: Abad Ruiz
Email: send email
Telefono: +34 91 5668852
Fax: +34 91 5668913

ES (MADRID) participant 367˙785.00
6    INSTITUT PASTEUR

 Organization address address: RUE DU DOCTEUR ROUX 25-28
city: PARIS CEDEX 15
postcode: 75724

contact info
Titolo: Dr.
Nome: Thierry
Cognome: Planchenault
Email: send email
Telefono: +33 1 44389113
Fax: +33 1 40613940

FR (PARIS CEDEX 15) participant 350˙000.00
7    UNIVERSITE JOSEPH FOURIER GRENOBLE 1

 Organization address address: "Avenue Centrale, Domaine Universitaire 621"
city: GRENOBLE
postcode: 38041

contact info
Titolo: Ms.
Nome: Leslie
Cognome: Hollett
Email: send email
Telefono: +33 4 76514488
Fax: +33 4 76635956

FR (GRENOBLE) participant 303˙528.00
8    VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED

 Organization address address: Dubravska Cesta 9
city: BRATISLAVA
postcode: 84505

contact info
Titolo: Ms.
Nome: Irena
Cognome: Ginzeryová
Email: send email
Telefono: +421 2 59302403
Fax: +421 2 54774284

SK (BRATISLAVA) participant 279˙750.00
9    HEINRICH-PETTE-INSTITUT FUER EXPERIMENTELLE VIROLOGIE UND IMMUNOLOGIE AN DER UNIVERSITAET HAMBURG

 Organization address address: Martinistrasse 52
city: HAMBURG
postcode: 20251

contact info
Titolo: Dr.
Nome: Nicole
Cognome: Nolting
Email: send email
Telefono: +49 40 48051104
Fax: +49 40 48051103

DE (HAMBURG) participant 199˙800.00
10    INTE:LIGAND SOFTWARE-ENTWICKLUNGS- UND CONSULTING GMBH

 Organization address address: Clemens-Maria Hofbauer Gasse 6
city: MARIA ENZERSDORF
postcode: 2344

contact info
Titolo: Dr.
Nome: Gerhard
Cognome: Wolber
Email: send email
Telefono: +43 699 1507 5000
Fax: +43 1 8174955 1371

AT (MARIA ENZERSDORF) participant 178˙100.00
11    PHILIPPS UNIVERSITAET MARBURG

 Organization address address: Biegenstrasse 10
city: MARBURG
postcode: 35032

contact info
Titolo: Dr.
Nome: Christian
Cognome: Veldman
Email: send email
Telefono: +49 6421 2826022
Fax: +49 6421 2826382

DE (MARBURG) participant 163˙800.00
12    MEDIZINISCHE UNIVERSITAET WIEN

 Organization address address: SPITALGASSE 23
city: WIEN
postcode: 1090

contact info
Titolo: Prof.
Nome: Markus
Cognome: Müller
Email: send email
Telefono: 431404000000
Fax: 431404000000

AT (WIEN) participant 6˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

resistance    cellular    avian    public          world    preclinical    recent    function    drugs    polymerase    influenza    academic    drug    anti    pandemic    expertise    replication    strains    structure    pathogenic    inhibitors    viral   

 Obiettivo del progetto (Objective)

'The 2009 H1N1 pandemic and the ongoing threat of highly pathogenic H5N1 strains have focused attention worldwide on the urgent need for effective anti-influenza drug options when the public is not protected by vaccination. The need is pressing since several circulating strains are resistant to currently stock-piled anti-neuraminidase drugs. In this project, we will exploit our recent advances in the detailed mechanistic understanding of the structure and function of the viral polymerase, the replication machine of the virus, to develop new drug candidates that inhibit viral replication in infected cells. The polymerase is an excellent drug target as it is highly conserved in all influenza A strains, whether of avian, swine or human origin. The project consortium includes 12 academic and SME partners from 6 European countries chosen for their expertise and complementarity. The focused drug design programme will start with already existing patented small molecule hits against two different polymerase active site targets and use structure-based medicinal chemistry expertise to arrive at optimized leads to enter preclinical studies. The aim is to take one preclinical candidate to phase 1 clinical trials, with contingency plans in place to cover setbacks. In parallel, a world-leading network of European academic labs will continue fundamental research on influenza polymerase atomic structure, cellular function and role in inter-species transmission, which will feed back into the drug design programme with enhanced assays for polymerase inhibitors, improved understanding of how the inhibitors work in the cellular context and potential resistance mechanisms, as well as providing new targets for future anti-influenza drug-design. If successful, the project will provide new opportunities to treat both seasonal and pandemic flu and thus can have an enormous impact on world-wide public health and well-being as well as the competitiveness of the European pharmaceutical sector'

Introduzione (Teaser)

The 2009 pandemic and recent outbreaks of highly pathogenic avian influenza strains have highlighted the need for effective anti-viral drugs. A broad choice of drugs is necessary for treatment before a new vaccine becomes available to counter the problem of viral resistance.

Altri progetti dello stesso programma (FP7-HEALTH)

PURSTEM (2008)

"Utilisation of the mesenchymal stem cell receptome for rational development of uniform, serum-free culture conditions and tools for cell characterization"

Read More  

AIDA (2011)

Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics

Read More  

CATAFLU.OR (2008)

"OrganoCATAlytic approaches towards easily synthesized, economical, and high yielding oseltamivir derivatives"

Read More